No CYP affinity. No conceivable effects on PXR activation. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Rituximab is a chimeric human-murine anti-human antigen CD20 monoclonal antibody.
Therapeutic characteristics
Rituximab is used, alone or as part of combination therapy, in the treatment of non-Hodgkins lymphomas. It is administered as an intravenous infusion. Common adverse reactions of rituximab that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, dorsal pain, anxiety, agitation, insomnia and tachycardia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Hepatic exposure
Metabolism and pharmacokinetics
Rituximab is metabolized as endogenous IgG. Non-CYP metabolism.
IPNet drug reports
No.
Similar drugs
Explore alternative drugs in similar therapeutic classes
L01F /
L01FA or
go back.
References
#
Citation details
PMID
*
Drug reference publications
1.
McEvoy GK, editor. Rituximab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10).
2.
Sweetman SC, editor. Martindale: The complete drug reference. Rituximab. Pharmaceutical Press 2009.
*
Summary of Product Characteristics
3.
Norwegian medicines agency. Summary of Product Characteristics (SPC). Mabthera.
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.